Summit Therapeutics Inc. — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Summit reported updated overall survival data from Phase III HARMONi trial showing consistent efficacy across Western and Asian patient populations (HR 0.76 for both subgroups, median follow-up 23.2 months Western, 32.7 months Asian). Akeso's HARMONi-6 study demonstrated ivonescimab plus chemotherapy achieved statistically significant OS benefit over tislelizumab plus chemotherapy in squamous NSCLC (HR 0.66, p=0.0017)—first head-to-head Phase III showing superiority over anti-PD-1 regimen in any tumor type. BLA for EGFRm NSCLC post-TKI setting accepted by FDA in January 2026 with PDUFA goal date November 14, 2026. Cash position: $690.7M (versus $713.4M December 31, 2025); company raised $230.8M via ATM in Q2 2026 plus additional $68.4M post-quarter.
Why this rating
Significant clinical validation (first anti-PD-1 head-to-head win) plus imminent FDA decision in core indication materially strengthen approval prospects. Relative to $2.5B market cap, near-term regulatory catalyst is meaningful but de-risks only one indication; cash runway supports multi-indication development.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.